Most peptides spread out through the body and hope to land somewhere useful. SS-31 does the opposite. It heads to one specific address: the inner membrane of your mitochondria, the tiny power plants inside nearly every cell you have. That single-minded focus is the whole point, and it's why this compound keeps coming up in longevity conversations.
You'll also see it called elamipretide, or MTP-131, or its old clinical-trial name, Bendavia. Same molecule. It has been studied in people further than most research peptides, and in September 2025, under the brand name Forzinity, it became the first FDA-approved mitochondria-targeted drug, cleared for improving muscle strength in Barth syndrome, a rare genetic condition. Outside that one approval, it's still investigational: the heart failure trials didn't hit their main goals, and it isn't approved for the energy, longevity, or cognitive uses researchers are actually exploring it for.
What it actually is
SS-31 is a tiny lab-made peptide, just four building blocks long. Its design lets it slip through cell membranes and concentrate inside the mitochondria, pulled in by the electrical charge those structures carry. Once there, it binds to a fat molecule called cardiolipin that lives only in the inner mitochondrial membrane.
Here's why that matters in plain terms. Cardiolipin is like the scaffolding that holds your cellular energy machinery in the right shape. When that scaffolding gets damaged by oxidative stress, your mitochondria become less efficient and start leaking more damage-causing molecules, which damages the scaffolding further. It's a downward spiral. SS-31 is studied as a way to interrupt that spiral and keep the scaffolding intact, so the power plant keeps running cleanly.
Why women in midlife are paying attention
Mitochondria are not an abstract science topic when you're living through perimenopause. The fatigue that sleep doesn't fix, the sense that your stamina dropped a level without warning, the muscle that softens even though nothing about your routine changed: a lot of that traces back to how well your cells are making and using energy. Mitochondrial function declines with age, and the hormonal shifts of midlife layer on top of that.
This is where SS-31's narrow focus gets interesting for women specifically. You'll hear about it mostly in the longevity and cardiology worlds. But the research that catches attention is the muscle work. Aged muscle becomes less responsive to the signal that tells mitochondria to ramp up energy production, and that sluggishness is part of why strength and endurance fade. SS-31 is studied as a way to restore some of that responsiveness, which speaks directly to the midlife experience of doing everything right and still feeling like your engine lost a cylinder.
What the research actually shows
Be clear-eyed here. The strongest, most consistent SS-31 data come from studies in mice and from isolated mitochondria in the lab, not from large human trials. In aged mouse hearts, treatment reduced age-related damage to important cardiac proteins. In mouse models of high-blood-pressure heart strain, it was linked to less scarring and less structural damage to mitochondria.
SS-31 has been studied in Phase 2 trials for heart failure and in the TAZPOWER trial for Barth syndrome, a rare mitochondrial cardiomyopathy. The Barth syndrome trial showed real improvement in muscle strength and exercise capacity, strong enough that it's now an FDA-approved treatment (Forzinity, approved September 2025). The heart failure trials told a different story: two separate Phase 2 studies, in two different types of heart failure, both missed their main goals. That's the honest split: a genuine clinical win in the specific rare disease where cardiolipin damage is the core problem, and no proven benefit yet in the broader heart conditions the drug was also tested for. The one finding with the most translational weight for non-cardiac use involved human muscle tissue: researchers reported that SS-31 quickly improved how aged muscle mitochondria respond to their energy-demand signal, and they saw it in both rodent and human samples. Human-tissue results are rarer and harder to wave away.
Where research and community diverge
The clinical trials studied SS-31 for heart conditions. The research community is largely using it for everything else. It's worth knowing that gap exists.
| What formal research has studied | What community researchers report using it for |
|---|---|
| Heart failure (HFpEF, Barth syndrome) | Energy and fatigue (especially perimenopause-related) |
| Mitochondrial disease | Brain fog and cognitive sharpness |
| Exercise capacity in heart patients | Recovery after exertion |
| Age-related cardiac function (animal) | General longevity and cellular aging |
The community is extrapolating from a solid mechanistic foundation to applications that make biological sense but haven't been tested in human trials. That's an informed extrapolation. It's not the same as having no basis, but it's worth knowing that's what it is.
What community researchers report, and when
This reflects what researchers report in community settings. It is not clinical data, is not verified by PPL, and doesn't constitute evidence of efficacy. Individual experiences vary significantly.
Weeks 1–2: Most people report nothing obvious. Some note mild changes in sleep quality. This is consistent with a compound working at the cellular energy level; changes aren't felt the way stimulants are.
Weeks 3–6: This is where reports diverge most. A segment reports noticeable changes in subjective energy, described variously as "easier to sustain effort," "less afternoon crash," or "recovery feels faster." Another segment reports nothing through this window.
8–12 weeks: Researchers who report positive outcomes most commonly identify changes in this window: sustained energy, reduced perception of fatigue during exertion, and (in women managing perimenopause fatigue specifically) some reports of meaningful improvement. A subset report nothing and discontinue.
What appears to affect outcomes: dosing protocol, injection site (see protocols below), peptide purity (this matters more for SS-31 than for simpler compounds), and baseline mitochondrial health.
Community protocols
Community-reported protocols only. Not clinical guidelines, not PPL recommendations, not medical advice.
| Parameter | Range reported | Notes |
|---|---|---|
| Weekly dose | 5–20 mg | Most common: 10 mg/week split across 5 days (2 mg/day) |
| Single injection | 1–4 mg | More common in higher-frequency protocols |
| Frequency | Daily to 3×/week | Daily appears more common in community protocols |
| Route | Injected just under the skin | Some IM reports; under-the-skin most discussed |
| Cycle length | 4–12 weeks | Some researchers run it ongoing |
| Reconstitution | Bacteriostatic water | Standard |
On injection site: The community has an ongoing discussion about whether injection site under the skin matters for a compound targeting mitochondria systemically. The weight of discussion leans toward systemic effect regardless of site, consistent with SS-31's mechanism. The formal cardiac trials used injections just under the skin of the abdomen.
Enter your vial, bac water amount, target dose, and syringe — and we'll tell you exactly where to draw to.
The SS-31 then FOXO4-DRI question
Some practitioners talk about sequencing SS-31 before FOXO4-DRI, and the logic is worth understanding even if you never go near either one.
The two compounds do different jobs. SS-31 is studied for repairing and supporting the mitochondria inside cells you want to keep. FOXO4-DRI belongs to a different category called senolytics, which are studied for clearing out "senescent" cells: old, damaged cells that stop dividing but linger and give off inflammatory signals. The thinking behind running SS-31 first is a priming idea. Repair and stabilize the mitochondria in your healthy cells first, so those cells are in better shape before you ask the body to clear out the damaged ones. Some frame it as tidying the house before you start throwing things away.
The honest caveat: this sequencing protocol is a practitioner theory, not something validated in human trials. There is no established human dosing for either compound, no published study confirming that this order produces better outcomes, and no long-term safety data for the pairing. The mechanistic story is tidy, but a tidy story is not evidence.
Purity and sourcing
SS-31 is one of the harder peptides to synthesize correctly, and purity matters more here than with simpler compounds. The CAS number for elamipretide is 736992-21-5; a COA should reference that specifically. Look for ≥98% purity by HPLC from a named third-party lab. See current SS-31 prices and vendor COA status in the price tool.
The honest part
Step back and the picture is consistent: a compound with genuinely interesting biology, a real but still-developing human dataset for cardiac applications, and a lot of confident protocol talk that runs well ahead of the science for longevity and energy applications. Long-term effects in humans are not established. The research-grade powder vendors sell is not the same as the pharmaceutical-grade material used in trials. If you're considering it, that gap between the lab story and the human evidence is the thing to sit with, and a knowledgeable healthcare provider is the right person to talk it through with.